| Identification | Back Directory | [Name]
MYCi975 | [CAS]
2289691-01-4 | [Synonyms]
MYCi975
NUCC-0200975
[1,1'-Biphenyl]-2-ol, 4'-chloro-6-[(4-chlorophenyl)methoxy]-3-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-3'-(trifluoromethyl)- | [Molecular Formula]
C25H16Cl2F6N2O2 | [MDL Number]
MFCD32263413 | [MOL File]
2289691-01-4.mol | [Molecular Weight]
561.3 |
| Chemical Properties | Back Directory | [Boiling point ]
566.5±50.0 °C(Predicted) | [density ]
1.45±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO:56.0(Max Conc. mg/mL);99.8(Max Conc. mM) | [pka]
7.99±0.50(Predicted) |
| Hazard Information | Back Directory | [Description]
MYCi975 is an inhibitor of the protein-protein interaction between Myc and Myc-associated factor X (MAX).1 It binds to Myc (Kd = 2.75 µM) and increases GSK3β-mediated Myc phosphorylation in a cell-free assay. MYCi975 (5 and 10 µM) decreases the viability of MyC-CaP and LNCaP prostate cancer cells. It induces apoptosis in a panel of 11 breast cancer cell lines when used at a concentration of 10 µM.2 In vivo, MYCi975 (100 mg/kg) reduces tumor volume in a MyC-CaP mouse xenograft model.WARNING This product is not for human or veterinary use. |
|
|